MedChemComm

CONCISE ARTICLE

Design, synthesis and bioevaluation of tacrine hybrids with cinnamate and cinnamylidene acetate derivatives as potential anti-Alzheimer drugs†

Catarina Quintanova,a Rangappa S. Keri,ac Sérgio M. Marques,a Maria G-Fernandes,d Sandra M. Cardoso,de M. Luisa Serralheirob and M. Amélia Santos*a

A series of novel tacrine–cinnamate and tacrine–cinnamylidene acetate hybrids have been designed, synthesized and evaluated as multitarget compounds for the treatment of Alzheimer’s disease. Results of the assessment of their inhibitory activity against acetylcholinesterase (AChE), antioxidant activity and self-induced β-amyloid (Aβ) aggregation are reported. These hybrid compounds showed promising results: all presented high activity against AChE, with IC_{50} values between the low micromolar and nanomolar range of concentrations. The molecular modeling studies suggested dual interaction with both the catalytic and peripheral sites. Some compounds presented good antioxidant activity (DPPH free radical method) in the low micromolar range, namely the cinnamate derivatives with hydroxyl substituents and extended allyl-conjugation. Moreover, these compounds showed good neuroprotective effects by rescuing neuroblastoma cells stressed with the β-amyloid peptide and hydrogen peroxide. Overall, our results suggest that some of these new hybrids have good potential as multifunctional drug candidates for AD treatment.

1. Introduction

Alzheimer’s disease (AD) is a serious neurodegenerative disorder characterized by progressive cognitive decline and irreversible memory loss. Although the etiology of AD is not well understood, there is a substantial amount of evidence about the existence of multiple factors that may play important roles in the disease pathophysiology, such as the deposit of aberrant proteins (e.g. extracellular β-amyloid (Aβ) and intracellular τ-protein), low levels of acetylcholine (ACh), oxidative stress in the central nervous system and dyshomeostasis of biometals.1–3 Despite great research efforts on the development of new AD therapies, aimed at targeting the main pathological hallmarks of the disease, including the amyloid plaque formation, to date they have not yet resulted in clinically effective treatments. The only approved treatments for AD patients are currently based on acetylcholinesterase inhibitors (AChEIs) (e.g. tacrine, galantamine, donepezil and rivastigmine) which improve the cholinergic neurotransmission and the symptomatic cognitive loss, but are ineffective in advanced stages of the disease.4

The complex multi-etiological nature of AD is believed to be responsible for the absence of disease-modifying drugs. In order to address this issue a new multitarget-based strategy has recently emerged. Thereby, we and other researchers have recently been involved in the development of molecular entities with the ability to simultaneously affect multiple disease pathways instead of only one.5,6 Many multipotent compounds have been designed and studied based on repositioning well known AChEI classical drugs, such as tacrine which has been hybridized with a variety of functional moieties, including two cinnamate derivatives.7–11

Following identical multitargeting design strategy, and based on our previous results on hydroxycinnamate hybrids with anti-oxidant and anti-neurodegenerative properties12 as well as tacrine hybrids,8 we have developed herein a new series of tacrine hybrids bearing moieties with a set of derivatives of cinnamic and cinnamylidene acetic acid (see Fig. 1). Following this strategy we aimed to develop new agents able to simultaneously address symptomatic and etiological routes...
in a possible AD therapy, such as cholinergic impairment, oxidant stress, and Aβ aggregation. Some derivatives of cinnamic acid and cinnamylidene acetic acid (5-phenyl-2,4-pentadienoic acid) are of natural origin, and have important biological properties such as antimicrobial and anti-cancer activities. Phenolic derivatives, such as caffeic acid and other hydroxycinnamic derivatives, have been considered as multifunctional antioxidants because, besides the more usual radical scavenging roles by electron or hydrogen-donation to the existing radicals, they are also able to chelate redox-active metal ions, thus disabling their participation in the Fenton reaction.

In our design strategy, the main purpose was to extend the double-bond conjugation of the cinnamate systems aimed at enhancing the anti-oxidant activity due to the expected stabilization of the phenoxyl radical formed, as well as extra interactions with Aβ peptides. The size of the linker between the two main aromatic moieties was selected to enable a bimodal AChE–ligand binding interaction with the two major AChE sub-sites (the catalytic anionic site, CAS, and the peripheral anionic site, PAS) and, ultimately improve their inhibitory activity as compared to the simple tacrine. Different aromatic substituents at the cinnamoyl moiety were included to provide some differentiation and balance among the antioxidant properties and the interactions with the enzyme’s active site. It should be mentioned that while this research project was ongoing, other studies on tacrine–cinnamate hybrids were published. Also, an interesting work was very recently reported, as a synthetic renewal in tacrine–ferulic acid hybrids, with an extrafunctionalization at the amide link by a multicomponent synthetic approach.

Herein, we describe the design and synthesis of a set hybrid compounds based on the conjugation of tacrine with a set of cinnamate and cinnamylidene acetate derivatives, with different substituent groups and linkers, which were investigated for their anti-oxidant, anticholinesterase and anti-Aβ aggregating activities. Finally, these compounds were bioassayed with neuronal cells stressed with Aβ and hydrogen peroxide (H₂O₂) for their potential neuroprotective roles.

2. Results and discussion

2.1. Molecular modeling

The strategy followed for the design of these new inhibitors was similar to previous works, which consisted of the selection of two main molecular scaffolds to account for the biological properties associated with Alzheimer’s disease. In this case, we have selected tacrine and a set of cinnamate-based moieties (Fig. 1) to endow the hybrids with anti-AChE and anti-oxidant properties, respectively. Then, the length and the type of linker (n and p parameters, Fig. 1) were varied in order to tune the best interactions possible with the gorge-lining residues.

In order to confirm the expected binding modes of the new hybrid compounds with AChE and attempt to predict their relative inhibitory strength, we have performed docking studies with this enzyme. The catalytic site of this enzyme is located near the bottom of a narrow ~20 Å-deep gorge, where the substrate (acetylcholine) is hydrolyzed into acetic acid and choline. This site is formed by three amino acids, Ser200, His440 and Glu327 (sequence numbering of Torpedo Californica AChE, TcAChE), which are essential for the catalytic enzymatic activity and are known as the ‘catalytic triad’. There are two main sites of binding for the AChE inhibitors, the catalytic anionic site (CAS), formed by three important amino acid residues, Trp84, Glu199 and Phe330, located at the lower part of the gorge, and the peripheral anionic site (PAS), located at the entrance of the gorge.
The docking studies were performed using the program GOLD, version 5.1. The crystal structure of TcAChE complexed with an inhibitor (N-4’-quinolyl-N’-9”-(1”″,2”″,3”″,4”″-tetrahydroacridinyl)-1,8-diaminoctane; PDB entry 1ODC) was used due to the structural similarities between the ligand in this complex and those in this study. In fact, the ligand in this crystal structure is also a bifunctional inhibitor containing tacrine and an aromatic moiety connected by a long alkylene linker. Hence, the protein conformation in this complex is expected to be similar to those with our ligands. The docking calculations were performed using the ASP scoring function, since this function has previously proven to give the best docking predictions for AChE inhibitors, and followed the same protocol.

The docking studies revealed that several aromatic interactions were established between the new compounds and the amino acid residues of the active site of AChE. The binding modes found for these inhibitors were very similar, differing only slightly from each other. Representative results of the docking studies are presented in Fig. 2, which shows compounds 6a and 9b well inserted in the cavity of the active center, blocking the accessibility of the active site to the substrate and water molecules. The tacrine moiety was always found inserted in the bottom of the gorge of the enzyme, binding to CAS by π–π stacking with the aromatic side chains of residues Trp84 and Phe330, very similarly to the tacrine moiety of the original ligand (Fig. 2a). The short distances between the carbonyl oxygen of His440 and the pyridinic nitrogen of tacrine (ranging from 2.7 to 3.3 Å) indicate the existence of a hydrogen bond between the tacrine pyridinium group and the carbonyl oxygen of His440, as previously reported for other tacrine-based inhibitors; this can be rationalized by the expected pKₐ value (ca. 8–9) of the tacrine moiety and the shift of the pyridine–pyridinium tautomeric equilibrium in the CAS. Generally, the different spacers were found accommodated along the hydrophobic cavity. The moiety of the cinnamic acid derivatives and the corresponding cinnamylidene analogs were always placed at the entrance of the gorge and were able to form favorable sandwich interactions with the aromatic side chains of residues Trp279 and Tyr70 of PAS.

Fig. 2b displays the structure of the 9b-AChE complex resulting from the docking simulation, which reveals the same π–π stacking interactions between the quinoline ring of tacrine and the CAS residues, as observed for the other ligands. At the other end, the benzene ring of the cinnamate moiety could also establish π–π stacking interactions with the same aromatic residues of PAS. The major differences in the described interactions arise from the substitution of the cinnamate benzene ring with methoxy groups, which may establish extra van der Waals interactions with some of the residues around PAS. Furthermore, the docking studies also suggest a possible hydrogen bond between an NH group of the chain spacer and a hydroxyl group of Tyr121. These interactions may explain the better results of AChE inhibition for compounds 9a–c (Table 1). The four compounds with OH groups in the benzene ring displayed the same main interactions mentioned above, but with the further ability to establish a hydrogen bond with the Ile275 residue above PAS (Fig. S1†). However, some of the favorable hydrophobic interactions with the methoxy groups are not possible with compounds 11.

Besides the key ligand–enzyme interactions described above, some differences in the inhibitory activities may be
mainly explained by the different ring-substituent groups of the cinnamic moiety and the spacer sizes. However, the docking calculations with compounds with longer spacers, (e.g. with four carbon atoms, \( n = 4 \), in the alkylenediamine chain) evidenced that the cinnamic moiety may potentially outstretch towards the bulk solvent, which may result in a lower interaction between the compounds and the enzyme, and concomitantly higher IC_{50} values (Table 1).

Globally, since the binding modes found for these compounds were so similar to each other, their relative potency as inhibitors would be difficult to predict with confidence. More importantly, the modeling studies allowed us to confirm the expected ability of the compounds to interact with both the CAS and PAS of AChE, thus explaining some of the strong inhibitory activities observed toward AChE.

### 2.2. Chemistry

In this study, fourteen tacrine–cinnamate based conjugates, 5–9(a–c), were firstly synthesized as shown in Scheme 1. The

**Table 1** Biological properties of the synthesized compounds. AChE inhibition and antioxidant activity (DPPH method)

<table>
<thead>
<tr>
<th>Compds</th>
<th>n</th>
<th>p</th>
<th>R_1</th>
<th>R_2</th>
<th>AChE inhibition IC_{50} (μM) ± SD</th>
<th>Antioxidant activity % (1 mM)</th>
<th>Aβ aggreg. inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>5a</td>
<td>2</td>
<td>1</td>
<td>H</td>
<td>H</td>
<td>0.77 ± 0.02</td>
<td>7.9</td>
<td></td>
</tr>
<tr>
<td>5b</td>
<td>3</td>
<td>1</td>
<td>H</td>
<td>H</td>
<td>0.38 ± 0.08</td>
<td>16.3</td>
<td></td>
</tr>
<tr>
<td>5c</td>
<td>4</td>
<td>1</td>
<td>H</td>
<td>H</td>
<td>0.85 ± 0.1</td>
<td>22.5</td>
<td></td>
</tr>
<tr>
<td>6a</td>
<td>2</td>
<td>2</td>
<td>H</td>
<td>H</td>
<td>0.32 ± 0.2</td>
<td>15.6</td>
<td></td>
</tr>
<tr>
<td>6b</td>
<td>3</td>
<td>2</td>
<td>H</td>
<td>H</td>
<td>0.29 ± 0.04</td>
<td>16.9</td>
<td></td>
</tr>
<tr>
<td>6c</td>
<td>4</td>
<td>2</td>
<td>H</td>
<td>H</td>
<td>0.62 ± 0.1</td>
<td>23.0</td>
<td></td>
</tr>
<tr>
<td>7a</td>
<td>2</td>
<td>1</td>
<td>OCH_2O</td>
<td></td>
<td>0.18 ± 0.05</td>
<td>12.2</td>
<td></td>
</tr>
<tr>
<td>7b</td>
<td>3</td>
<td>1</td>
<td>OCH_2O</td>
<td></td>
<td>0.13 ± 0.04</td>
<td>15.4</td>
<td></td>
</tr>
<tr>
<td>7c</td>
<td>4</td>
<td>1</td>
<td>OCH_2O</td>
<td></td>
<td>0.73 ± 0.1</td>
<td>18.6</td>
<td></td>
</tr>
<tr>
<td>8a</td>
<td>2</td>
<td>2</td>
<td>OCH_2O</td>
<td></td>
<td>0.30 ± 0.03</td>
<td>26.2</td>
<td></td>
</tr>
<tr>
<td>8b</td>
<td>3</td>
<td>2</td>
<td>OCH_2O</td>
<td></td>
<td>0.13 ± 0.03</td>
<td>72.2</td>
<td></td>
</tr>
<tr>
<td>9a</td>
<td>2</td>
<td>1</td>
<td>OCH_3</td>
<td>OCH_3</td>
<td>0.09 ± 0.02</td>
<td>8.8</td>
<td></td>
</tr>
<tr>
<td>9b</td>
<td>3</td>
<td>1</td>
<td>OCH_3</td>
<td>OCH_3</td>
<td>0.09 ± 0.01</td>
<td>36.5</td>
<td></td>
</tr>
<tr>
<td>9c</td>
<td>4</td>
<td>1</td>
<td>OCH_3</td>
<td>OCH_3</td>
<td>0.39 ± 0.1</td>
<td>16.1</td>
<td></td>
</tr>
<tr>
<td>10a</td>
<td>2</td>
<td>2</td>
<td>OH</td>
<td>OH</td>
<td>0.84 ± 0.07</td>
<td>12.3 μM^g</td>
<td></td>
</tr>
<tr>
<td>10b</td>
<td>3</td>
<td>2</td>
<td>OH</td>
<td>OH</td>
<td>0.98 ± 0.13</td>
<td>11.3 μM^g</td>
<td></td>
</tr>
<tr>
<td>11a</td>
<td>2</td>
<td>2</td>
<td>OH</td>
<td>OH</td>
<td>1.09 ± 0.2</td>
<td>9.5 μM^g</td>
<td></td>
</tr>
<tr>
<td>11b</td>
<td>3</td>
<td>2</td>
<td>OH</td>
<td>OH</td>
<td>0.48 ± 0.02</td>
<td>9.1 μM^g</td>
<td></td>
</tr>
<tr>
<td>Tacrine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.19 ± 0.02</td>
<td>&gt;1^d</td>
<td></td>
</tr>
<tr>
<td>Cinnamic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9900 ± 700^f</td>
<td>663^b</td>
<td></td>
</tr>
<tr>
<td>Caffeic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5531^e</td>
<td>24.8^h</td>
<td></td>
</tr>
</tbody>
</table>

The values presented are the mean of three independent experiments ± SD (standard deviation). Percentage of inhibition of antioxidant activity for 1 mM concentration. Standard deviation is within 10% of the values. Antioxidant activity, EC_{50} Standard deviation is within 10% of the values. Literature value, EC_{50} > 1 mM. Literature value. Inhibition of self-mediated Aβ(42) aggregation (%). The thioflavin T fluorescence method was used, and the measurements were carried out in the presence of an inhibitor (80 μM); SEM < 10%. Literature value for Aβ(40), in the presence of an inhibitor (20 μM). Literature value, EC_{50} (μM).

Scheme 1 Reagents and conditions: a) Phenol, KI, 4 h, 180 °C; b) CH_2Cl_2, T3P, NMM, 4 h, N_2; c) BCl_3, n-Bu_4NI, CH_2Cl_2, -78 °C, N_2.
2.3. AChE inhibition

The results of AChE inhibitory activities obtained for the set of hybrid compounds and tacrine are summarized in Table 1; this assessment was based on an adaptation of a protocol previously described. In general, all the compounds displayed high inhibitory activities with IC₅₀ values mostly in the sub-micromolar range, as would be expected from enclosing a tacrine moiety. Some of the newly synthesized compounds, 9a-b, 7a-b and 8b, revealed better inhibitory activities (IC₅₀ = 0.09–0.18 μM) than tacrine. The best inhibitors were 9a and 9b (IC₅₀ = 0.09 μM) with 3,4-dimethoxy substitutions in the cinnamate unit; compounds 7a and 7b with methylenedioxy substituents (O-CH₂-O) also exhibited high inhibitory potency (IC₅₀ = 0.18 and 0.13 μM, respectively). Regardless of the effect of the linkers, these results confirm that these nonpolar groups allow favorable interactions with some PAS hydrophobic amino acids and enhance the stability of the protein–ligand complex, as predicted by the modeling studies. The difference between 7a and 7b could be due to the size of the spacer, namely the spacer with 3 carbon atoms which may provide the optimal length for the interaction of the cinnamic moiety with PAS residues.

A more detailed analysis of the inhibitory results revealed that the activity is lower for the tacrine-cinnamate hybrids unsubstituted at positions 3 and 4 or substituted by hydroxyl groups. Additionally, for all spacers (n = 2, 3 and 4), the presence of 3- and 4-methoxy substituent groups leads to IC₅₀ values lower than those of the corresponding non-substituted analogues. Another factor that influences the AChE inhibition is the extension of the double bond between the benzene ring and the carboxyl group which allows stronger hydrophobic interactions between the ligands and AChE.

The compounds containing free OH groups, 10a-b and 11a-b, displayed higher IC₅₀, which may be rationalized by their increased polar character that reduces the interactions within the PAS of AChE, and therefore exhibit lower enzyme inhibitory capacity. However, the corresponding IC₅₀ values are still in the low micromolar range and, although less potent than tacrine or their less polar derivatives, they can still be considered quite active AChE inhibitors with potential application (especially taking into account other important associated properties).

In summary, the new hybrid compounds revealed interesting properties as AChE inhibitors, in some cases with higher activities than the reference drug (tacrine). Moreover, since they possess other potentially active functional groups, they may reveal more beneficial and efficient agents against AD than tacrine.

2.4. Antioxidant activity

The antioxidant activity or the free radical scavenging capacity of the synthesized tacrine-cinnamate hybrids was assessed through their interaction with the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH). Analysis of the results of anti-oxidant activity (see Table 1) shows that it is quite dependent on the cinnamate substituents. In particular, the compounds with two free hydroxyl groups (10a, 10b, 11b) showed the highest antioxidant activities (EC₅₀ in the low micromolar range). Although compounds 10a–b have been recently studied, our aim was beyond that, namely to study the effect of an extra conjugated double bond on the cinnamate derivatives and lead to the development of the homologous 11a–b. These results showed that the presence of a second double bond generally leads to a slight improvement of the anti-oxidant activity. Regarding the hybrids with non-substituted benzene rings or with protected hydroxyl substituents, only moderate antioxidant activity was found (%AA in the millimolar range), similar to those previously reported for several cinnamic acid derivatives. Among these compounds, 8a, which resulted from the extension of the conjugated double bond of compound 7a, presented the highest activity (26.2%). Except for the hydroxyl groups, the other cinnamate substituents groups do not sensibly affect the antioxidant activity.

Therefore, as anticipated, the presence of phenolic hydroxyl groups considerably increased the antioxidant activity, with EC₅₀ values in the low micromolar range, in close similarity to those reported for 10a and 10b (14.1 and 11.1 μM, respectively). This may be due to the fact that these antioxidants possess one extra mechanism of action, as compared with the hydroxyl protected analogues. In fact, similar to that reported for the analogue caffeic acid, the hybrids containing cis-phenolic (or catechol) groups, 10a-b and 11a-b can form chelates with trivalent (Fe, Al) and divalent (Cu, Zn) metal ions. However, especially relevant for their anti-oxidant role is their high chelating capacity for redox-active metal ions, such as iron and copper, well-known catalysts of oxidative stress.

Conversely, the deprotection of the phenolic groups is expected to decrease the lipophilicity of the compounds and...
considered as drug candidates for oral administration and compounds, they fulfill most of the drug-like criteria to be +2 (active) scale. Thus, these results indicate that, notwith-
in the CNS, the program Qikprop does not supply accepted
penetrate the blood
gram QikProp, the range between
24 h. Each solution was further incubated for 5 min with a
ried out by incubating A
indicates moderate to high octanol/water log
P
and lead to only one violation of the
Lipinski’s rule of five were calculated in order to analyze their
druglikeliness for potential oral use as anti-AD agents.
Analysis of the results of in silico screening (Table S1↑) indicates moderate to high octanol/water log P coefficient (clog P) for all the compounds. The high lipophilic character (>5.0) calculated for some compounds, namely those containing hydroxyl protected groups or longer chain spacers, may make difficult their transport through the blood strain. However, their molecular weights are lower than 500 g mol⁻¹ and lead to only one violation of the Lipinski’s rule of five (clog P > 5). The Caco-2 permeability rates (>500 nm s⁻¹ is considered good) indicate that the absorption through the intestinal tract to the blood is possible. Also, the compounds with negative log BB values should have good blood–brain permeability. In fact, according to the limits given by the program QikProp, the range between −3.0 and +1.0 is acceptable; however values of log BB less than −1.0 are considered poor, whereas drugs with 0.3 are considered good and are able to penetrate the blood–brain barrier. Regarding the drug activity in the CNS, the program QikProp does not supply accepted limits, but categorizes the compounds on a −2 (inactive) to +2 (active) scale. Thus, these results indicate that, notwithstanding the generally high lipophilicity of most of these compounds, they fulfill most of the drug-like criteria to be considered as drug candidates for oral administration and possible brain penetration.

2.5. Pharmacokinetic properties
To predict the potential of the new compounds as eventual drugs, some descriptors of their pharmacokinetic profiles were determined, through the use of the program QikProp, v.2.5.35 Parameters such as the lipo/hydrophilic character (clog P), the ability to cross the blood–brain barrier (log BB), the ability to be absorbed through the intestinal tract to the blood (Caco-2 cell permeability) and the verification of Lipinski’s rule of five were calculated in order to analyze their druglikeliness for potential oral use as anti-AD agents.

Analysis of the results of in silico screening (Table S1↑) indicates moderate to high octanol/water log P coefficient (clog P) for all the compounds. The high lipophilic character (>5.0) calculated for some compounds, namely those containing hydroxyl protected groups or longer chain spacers, may make difficult their transport through the blood strain. However, their molecular weights are lower than 500 g mol⁻¹ and lead to only one violation of the Lipinski’s rule of five (clog P > 5). The Caco-2 permeability rates (>500 nm s⁻¹ is considered good) indicate that the absorption through the intestinal tract to the blood is possible. Also, the compounds with negative log BB values should have good blood–brain permeability. In fact, according to the limits given by the program QikProp, the range between −3.0 and +1.0 is acceptable; however values of log BB less than −1.0 are considered poor, whereas drugs with 0.3 are considered good and are able to penetrate the blood–brain barrier. Regarding the drug activity in the CNS, the program QikProp does not supply accepted limits, but categorizes the compounds on a −2 (inactive) to +2 (active) scale. Thus, these results indicate that, notwithstanding the generally high lipophilicity of most of these compounds, they fulfill most of the drug-like criteria to be considered as drug candidates for oral administration and possible brain penetration.

2.6. Inhibition of self-mediated Aβ42 aggregation
To test the capacity of a selection of the new synthesized hybrids to inhibit Aβ aggregation, in vitro assays with thio-
flavin T (ThT) were carried out, since ThT interacts with Aβ structures and may compete for binding to Aβ fibrils. To monitor the presence of fibrils, the ThT fluorescence emission was monitored at λem = 490 nm (λex = 446 nm).19,37 Within this wavelength range, the compounds do not exhibit any absorption (see Fig. S2 in the ESI†). The studies were carried out by incubating Aβ42 (40 μM) in the presence and in the absence of the selected compounds (80 μM) at 37 °C for 24 h. Each solution was further incubated for 5 min with a
ThT solution and afterwards the respective fluorescence emis-

2.7. Cell viability and effect in preventing Aβ42- and H2O2-
induced toxicity on neuroblastoma cells
The new hybrids were firstly submitted to an evaluation of the dose–response effect on neuroblastoma cells (SH-SY5Y), to select the highest non-toxic concentration to be used. Compounds with extended double conjugation (p = 2), (6a, 6b, 8a and 8b) appear, in general, more toxic than the corre-
sponding non-extended analogues (p = 1) (5a, 5b, 7a and 7b) (see ESI† Fig. S3). Also, compounds containing a methyl-
edioxy cinnamate substitution (7a–c and 8a–b) appeared more toxic than the corresponding analogues with other sub-
stituents. Both the double conjugation extension and the methylenedioxy substitution are associated with an increase in the lipophilic character (clog P > 5, Table S1†), which may account for toxicity enhancements. An identical toxicity increase was not observed for compounds 11a–b, as com-
pared with the analogues 10a–b eventually due to the hydroxyl cinnamate substituents which counterbalanced some of the lipophilicity increase. Interestingly, preliminary exploratory screenings of the toxicity of some of these comp-
pounds against ovarian cancer cells also showed toxicity in the μM range, and the corresponding IC₅₀ values followed an identical trend: 8b (2.50), 7b (5.82), 9a (10.4), 9b (19.5).38

The following selection of compound concentrations was used for the studies in cells: 2.5 μM for 5a–c, 7a, 7c and 9a–c; 1.5 μM for 6a–c, 7b and 8a–b; 5 μM for 10a–b and 11a–b. Even so, compounds 5b, 6a, 6c and 8a show an insignificant change in cell viability, when compared to the control.
The potential therapeutic action of these compounds was then assessed on neuroblastoma cells treated with the Aβ42 peptide, which is a reliable in vitro cellular model to screen new disease-modifying drugs, as it mimics some of the aspects of AD neurodegeneration. The quantitative colorimetric method with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction accounted for the viability of neuroblastoma cells, with or without compounds and/or Aβ42 peptide treatment.

Our results show that the 24 h treatment with the Aβ42 peptide (1 μM) results in a significant decrease in cell viability, when compared to the control. Most of the compounds were able to reduce the toxic effect of the Aβ42 peptide and increase the cell viability. Among them, compounds 5c (2.5 μM) and 9a (2.5 μM) evidenced the most significant protection against Aβ42-induced toxicity in neuroblastoma cells (Fig. 3A and B).

Due to the previous results obtained, compounds 5c, 9a–c, 10a–b and 11a–b were further selected to examine their neuroprotective effect against oxidative stress induced by hydrogen peroxide (H2O2). Our results show that the 24 h treatment with H2O2 (50 μM) induced a significant decrease...
in cell viability, when compared to the control. Most of the compounds tested (9a–c, 10b and 11a–b) were able to reduce the toxic effect of H2O2 and increase the cell viability. Among them, compounds 9a (2.5 μM), 9b (2.5 μM), 10b (5 μM) and 11a (5 μM) evidenced the most significant neuroprotective effect against H2O2-induced toxicity in neuroblastoma cells (Fig. 4).

Thus, compound 9a, which is able to block or hamper the toxic effects of Aβ42 and H2O2, may be considered a neuroprotector.

3. Conclusion

A series of bifunctional compounds based on tacrine hybridization with cinnamic acid and cinnamylidene acetic acid derivatives have been developed and biologically evaluated, aimed at gathering information about their potential application as anti-Alzheimer’s agents. Some compounds showed high AChE inhibitory activity (nanomolar range), even outperforming the tacrine drug, apparently due to a bimodal interaction. The compounds with free catechol moieties showed very high antioxidant activity, eventually due to their iron-chelating contribution. The cellular study performed with neuroblastoma cells treated with the Aβ42 peptide, a reliable cellular model of AD neurodegeneration, provided substantial evidence supporting the fact that compounds 5c and 9a show protective effects against Aβ42-induced cell toxicity. Additionally, compounds 9a–b, 10b and 11a afforded good neuroprotection against H2O2 toxic effects.

Collectively, the biological and physicochemical data obtained in this study allow us to propose the development of new tacrine–cinnamate derivatives as valuable multipotent drugs to arrest AD progression.

Acknowledgements

The authors thank Fundação para a Ciência e Tecnologia (FCT) for financial support with the projects PEst-OE/QUI/UI0100/2011 and UID/MULTI/00612/2013, the fellowships SFRH/BPD/75490/2010 and BL/CQE-2014-003, and also the Portuguese NMR and Mass Spectrometry Networks (IST-UTL Center and NODE CQE-IST/RNEM).

References

MSc Thesis


30 PDB, entry 1ODC, http://www.rcsb.org/pdb/explore/explore. do?structureId=1ODC.


41 QikProp, versão 2.5, Schrödinger, LLC, New York, NY, 2005.


44 Unpublished results.